Filing Flows › Sarepta Therapeutics (SRPT) › Q3 2026
Sarepta Therapeutics (SRPT) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Sarepta Therapeutics (SRPT) reported revenue of $381M for the third quarter 2026 (Q3 2026), -5% from a year earlier and -5% from the quarter before. Operating margin was -2.4%, net loss $28.5M (7.5% of revenue).
Sarepta Therapeutics, Q3 2026: revenue $381M (-4% year over year), operating margin -2.4%, net loss $28.5M, operating cash flow $60.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $381M | -5% | -5% |
| Operating profit | −$9.0M | -168% | — |
| Net earnings | −$28.5M | — | — |
| Operating cash flow | $60.0M | -70% | — |
| Free cash flow | $57.0M | -71% | — |
What changed
Revenue was $381.4M in Q3 2026, down 5% year over year and down 5% from the previous quarter. Pmo Products was the largest line at 63% of revenue. Elevidys lost $48.0M year over year (down 37%), 267% of the total change.
Operating costs exceeded revenue by $9.0M, an operating margin of -2.4%. The fastest-growing cost line was Other operating costs (+1494%). The quarter ended with a net loss of $28.5M, wider than the previous quarter's $4.9M loss. Net interest and other expense of $16.7M was the main reason.
Operating cash flow was $60.0M. Non-cash charges added back $5.9M of depreciation and amortization and $26.7M of share-based compensation. Working capital and other items added $55.8M. Capital expenditures of $2.9M left free cash flow of $57.0M.
Questions
What was Sarepta Therapeutics' revenue in the third quarter 2026?
Sarepta Therapeutics (SRPT) reported revenue of $381M for the third quarter 2026 (Q3 2026), -5% from a year earlier and -5% from the quarter before.
Was Sarepta Therapeutics profitable in the third quarter 2026?
Operating loss was $9.0M (-2.4% of revenue) and net loss $28.5M.